AT291247B - Verfahren zur Herstellung von neuen 1H-Imidazo[4,5-b]pyrazin-2-onen - Google Patents
Verfahren zur Herstellung von neuen 1H-Imidazo[4,5-b]pyrazin-2-onenInfo
- Publication number
- AT291247B AT291247B AT768868A AT768868A AT291247B AT 291247 B AT291247 B AT 291247B AT 768868 A AT768868 A AT 768868A AT 768868 A AT768868 A AT 768868A AT 291247 B AT291247 B AT 291247B
- Authority
- AT
- Austria
- Prior art keywords
- pyrazin
- imidazo
- ones
- preparation
- new
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US65904267A | 1967-08-08 | 1967-08-08 | |
| US72803368A | 1968-05-09 | 1968-05-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AT291247B true AT291247B (de) | 1971-07-12 |
Family
ID=27097746
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT768868A AT291247B (de) | 1967-08-08 | 1968-08-06 | Verfahren zur Herstellung von neuen 1H-Imidazo[4,5-b]pyrazin-2-onen |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US3507866A (de) |
| AT (1) | AT291247B (de) |
| BE (1) | BE719154A (de) |
| CH (1) | CH516574A (de) |
| DE (1) | DE1795062A1 (de) |
| DK (1) | DK123484B (de) |
| ES (1) | ES356976A1 (de) |
| FR (2) | FR1578366A (de) |
| GB (1) | GB1193035A (de) |
| IL (1) | IL30463A0 (de) |
| NL (1) | NL6810650A (de) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6858615B2 (en) | 2002-02-19 | 2005-02-22 | Parion Sciences, Inc. | Phenyl guanidine sodium channel blockers |
| US6903105B2 (en) * | 2003-02-19 | 2005-06-07 | Parion Sciences, Inc. | Sodium channel blockers |
| US20050090505A1 (en) * | 2003-08-18 | 2005-04-28 | Johnson Michael R. | Methods of reducing risk of infection from pathogens |
| US20090253714A1 (en) * | 2003-08-20 | 2009-10-08 | Johnson Michael R | Methods of reducing risk of infection from pathogens |
| US7745442B2 (en) * | 2003-08-20 | 2010-06-29 | Parion Sciences, Inc. | Methods of reducing risk of infection from pathogens |
| US7923041B2 (en) * | 2005-02-03 | 2011-04-12 | Signum Biosciences, Inc. | Compositions and methods for enhancing cognitive function |
| US20070021439A1 (en) * | 2005-07-25 | 2007-01-25 | Parion Sciences, Inc. | Methods of reducing risk of infection from pathogens with soluble amide and ester pyrazinoylguanidine sodium channel blockers |
| US8227603B2 (en) * | 2006-08-01 | 2012-07-24 | Cytokinetics, Inc. | Modulating skeletal muscle |
| DK2069352T5 (en) | 2006-08-02 | 2017-04-03 | Cytokinetics Inc | SPECIFIC CHEMICAL UNITS, COMPOSITIONS AND PROCEDURES |
| SI2069352T1 (sl) * | 2006-08-02 | 2013-12-31 | Cytokinetics, Inc. | Določene kemijske entitete, sestavki in postopki |
| US8299248B2 (en) | 2006-08-02 | 2012-10-30 | Cytokinetics, Incorporated | Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use |
| US7981893B2 (en) * | 2006-10-19 | 2011-07-19 | Signal Pharmaceuticals, Llc | Heteroaryl compounds, compositions thereof, and methods of treatment therewith |
| EP2139478A4 (de) * | 2007-03-30 | 2010-05-05 | Cytokinetics Inc | Bestimmte chemische entitäten, zusammensetzungen und verfahren |
| US8110578B2 (en) | 2008-10-27 | 2012-02-07 | Signal Pharmaceuticals, Llc | Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway |
| NZ618135A (en) | 2009-10-26 | 2015-05-29 | Signal Pharm Llc | Methods of synthesis and purification of heteroaryl compounds |
| AR086745A1 (es) | 2011-06-27 | 2014-01-22 | Parion Sciences Inc | 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida |
| US10272082B2 (en) | 2011-07-13 | 2019-04-30 | Cytokinetics, Inc. | Combination ALS therapy |
| KR101978537B1 (ko) | 2011-10-19 | 2019-05-14 | 시그날 파마소티칼 엘엘씨 | Tor 키나제 억제제를 사용한 암의 치료 |
| US9403829B2 (en) | 2011-12-02 | 2016-08-02 | Signal Pharmaceuticals, Llc | Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1H)-one, a solid form thereof and methods of their use |
| JP6114317B2 (ja) | 2012-02-24 | 2017-04-12 | シグナル ファーマシューティカルズ，エルエルシー | Ｔｏｒキナーゼ阻害剤の組合せ療法を用いて、非小細胞肺がんを処置する方法 |
| AU2013203714B2 (en) | 2012-10-18 | 2015-12-03 | Signal Pharmaceuticals, Llc | Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity |
| MX2015007797A (es) | 2012-12-17 | 2015-10-05 | Parion Sciences Inc | Compuestos de 3,5-diamino-6-cloro-n-(n-(4-fenilbutil) carbamimidoil) pirazin-2-carboxamida. |
| PE20151054A1 (es) | 2012-12-17 | 2015-08-07 | Parion Sciences Inc | Derivados de cloro-pirazin carboxamida con actividad bloqueadora sobre los canales de sodio epiteliales |
| MX2015009209A (es) | 2013-01-16 | 2016-03-17 | Signal Pharm Llc | Compuestos sustituidos de pirrolopirimidina, composiciones de los mismos, y metodos de tratamiento con los mismos. |
| CA2908353C (en) | 2013-04-17 | 2021-11-02 | Signal Pharmaceuticals, Llc | Treatment of cancer with dihydropyrazino-pyrazines |
| US9505764B2 (en) | 2013-04-17 | 2016-11-29 | Signal Pharmaceuticals, Llc | Treatment of cancer with dihydropyrazino-pyrazines |
| AU2014254059B2 (en) | 2013-04-17 | 2019-06-06 | Signal Pharmaceuticals, Llc | Combination therapy comprising a TOR kinase inhibitor and a cytidine analog for treating cancer |
| CA2908957C (en) | 2013-04-17 | 2021-05-18 | Signal Pharmaceuticals, Llc | Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer |
| HK1221168A1 (zh) | 2013-04-17 | 2017-05-26 | 西格诺药品有限公司 | 用於治疗癌症的包括tor激酶抑制剂和n-(3-(5-氟-2-(4-(2-甲氧基乙氧基)苯基氨基)嘧啶-4-基氨基)苯基)丙烯醯胺的组合疗法 |
| MX368286B (es) | 2013-04-17 | 2019-09-27 | Signal Pharm Llc | Terapia de combinacion que comprende un inhibidor de tor cinasa y un compuesto de quinazolinona 5-sustituida para tratar cancer. |
| EA030726B1 (ru) | 2013-04-17 | 2018-09-28 | СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи | ФАРМАЦЕВТИЧЕСКИЕ СОСТАВЫ, СПОСОБЫ, ТВЕРДЫЕ ФОРМЫ И СПОСОБЫ ПРИМЕНЕНИЯ, ОТНОСЯЩИЕСЯ К 1-ЭТИЛ-7-(2-МЕТИЛ-6-(1H-1,2,4-ТРИАЗОЛ-3-ИЛ)ПИРИДИН-3-ИЛ)-3,4-ДИГИДРОПИРАЗИНО[2,3-b]ПИРАЗИН-2(1H)-ОНУ |
| HK1223286A1 (zh) | 2013-05-29 | 2017-07-28 | 西格诺药品有限公司 | 7-(6-(2-羟基丙-2-基)吡啶-3-基)-1-((反式)-4-甲氧基环己基)-3，4-二氢吡嗪并[2，3-b]吡嗪-2(1h)-酮的药物组合物、其固体形式及它们的使用方法 |
| US9102633B2 (en) | 2013-12-13 | 2015-08-11 | Parion Sciences, Inc. | Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds |
| JP2017511367A (ja) | 2014-04-16 | 2017-04-20 | シグナル ファーマシューティカルズ，エルエルシー | １−エチル−７−（２−メチル−６−（１Ｈ−１，２，４−トリアゾール−３−イル）ピリジン−３−イル）−３，４−ジヒドロピラジノ［２，３−ｂ］ピラジン−２（１Ｈ）−オン及び共形成物を含む固体形態、その組成物及び使用方法 |
| NZ714742A (en) | 2014-04-16 | 2017-04-28 | Signal Pharm Llc | Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use |
| US9718824B2 (en) | 2014-04-16 | 2017-08-01 | Signal Pharmaceuticals, Llc | Solid forms comprising 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one, and a coformer, compositions and methods of use thereof |
| EP3131552B1 (de) | 2014-04-16 | 2020-07-15 | Signal Pharmaceuticals, LLC | Verfahren zur behandlung von krebs anhand einer tor-kinasehemmerkombinationstherapie |
| NZ629796A (en) | 2014-07-14 | 2015-12-24 | Signal Pharm Llc | Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use |
| EA201790189A1 (ru) | 2014-07-14 | 2017-11-30 | СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи | Способы лечения злокачественного новообразования с использованием замещенных пирролопиримидиновых соединений, композиции на их основе |
| ES2959860T3 (es) | 2017-06-22 | 2024-02-28 | Celgene Corp | Tratamiento del carcinoma hepatocelular caracterizado por la infección por el virus de la hepatitis B |
-
1968
- 1968-05-09 US US728033A patent/US3507866A/en not_active Expired - Lifetime
- 1968-07-26 NL NL6810650A patent/NL6810650A/xx unknown
- 1968-07-29 IL IL30463A patent/IL30463A0/xx unknown
- 1968-08-05 GB GB37296/68A patent/GB1193035A/en not_active Expired
- 1968-08-05 DE DE19681795062 patent/DE1795062A1/de active Pending
- 1968-08-06 ES ES356976A patent/ES356976A1/es not_active Expired
- 1968-08-06 AT AT768868A patent/AT291247B/de not_active IP Right Cessation
- 1968-08-07 DK DK379768AA patent/DK123484B/da unknown
- 1968-08-07 BE BE719154D patent/BE719154A/xx unknown
- 1968-08-07 CH CH1183068A patent/CH516574A/de not_active IP Right Cessation
- 1968-08-08 FR FR1578366D patent/FR1578366A/fr not_active Expired
- 1968-11-08 FR FR173159A patent/FR8409M/fr not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| GB1193035A (en) | 1970-05-28 |
| FR1578366A (de) | 1969-08-14 |
| NL6810650A (de) | 1969-02-11 |
| IL30463A0 (en) | 1968-09-26 |
| CH516574A (de) | 1971-12-15 |
| FR8409M (de) | 1971-03-31 |
| BE719154A (de) | 1969-02-07 |
| ES356976A1 (es) | 1970-10-16 |
| US3507866A (en) | 1970-04-21 |
| DK123484B (da) | 1972-06-26 |
| DE1795062A1 (de) | 1972-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CH505118A (de) | Verfahren zur Herstellung von 1,2,4-Triazin-5-onen | |
| AT275521B (de) | Verfahren zur Herstellung von neuen 1,4-Dihydropyridinderivaten | |
| CH481110A (de) | Verfahren zur Herstellung von 1,2,4,5-Tetrahydro-3-azepinen | |
| CH502364A (de) | Verfahren zur Herstellung von neuen 1,2,4-Oxadiazolen | |
| AT281836B (de) | Verfahren zur Herstellung von neuen 2-Methyl-3-carbonsäureamido-chinoxalin-di-N-oxiden-(1,4) | |
| AT277221B (de) | Verfahren zur Herstellung von neuen 5-Nitro-2-furyl-2-isoxazolin-derivaten | |
| CH496022A (de) | Verfahren zur Herstellung von neuen N,N'-Diglycidyl-Verbindungen | |
| AT291250B (de) | Verfahren zur Herstellung von neuen 5-NR<1>R<2> -6-Chlor-1H-imidazo[4,5-b]pyrazin-2-onen | |
| AT277985B (de) | Verfahren zur Herstellung von neuen Nitro-furan-, -thiophen- oder -pyrrol-derivaten | |
| CH498132A (de) | Verfahren zur Herstellung neuer Pyrido (1,2-a)-s-triazindione | |
| AT284128B (de) | Verfahren zur Herstellung von neuen 2-Halogenmethyl-3-carbansäureamido-chinoxalin-di-N-oxiden-(1,4) | |
| AT280271B (de) | Verfahren zur Herstellung von neuen Cumarinyl-v-triazoloxydderivaten | |
| AT281838B (de) | Verfahren zur Herstellung von neuen 2-Isothiuronium-methyl-3-carbonsäureamido-chinoxalin-di-N-oxid-(1,4)-halogeniden | |
| AT298476B (de) | Verfahren zur Herstellung von neuen Naphthylisopropylamin-Derivaten | |
| CH489525A (de) | Verfahren zur Herstellung von 1,8-Naphthyridinderivaten | |
| AT283356B (de) | Verfahren zur Herstellung von neuen 1,2,4-Oxdiazolidin-Derivaten | |
| CH508645A (de) | Verfahren zur Herstellung von neuen 5-substituierten y-Carbolinderivaten | |
| CH453370A (de) | Verfahren zur Herstellung von neuen 5,6-Dihydro-6-oxo-pyrido (2,3-b)(1,4)benzoxazepinen | |
| AT290026B (de) | Verfahren zur Herstellung von neuen 22-Amino-23,24-bisnorcholanderivaten | |
| AT293634B (de) | Verfahren zur Herstellung von neuen 17α-Acyloxy-11β-methyl-19-norpregn-4-en-3,20-dionen | |
| CH522619A (de) | Verfahren zur Herstellung von neuen Derivaten von 2a,3a-Epithioandrostanen | |
| AT291967B (de) | Verfahren zur Herstellung von neuen N-Phenyl-N-2-fluor-1,1,2,2,-tetrachloräthylsulfenyl-sulfamiden | |
| CH469729A (de) | Verfahren zur Herstellung von neuen 4,9-Dihydrothieno-(2,3-b)-benzo-(e)-thiepinderivaten | |
| AT281020B (de) | Verfahren zur Herstellung von neuen 3-Imino-1,2-benzisothiazolinen | |
| AT277254B (de) | Verfahren zur Herstellung von neuen Benzazepinopyridoindolderivaten |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ELJ | Ceased due to non-payment of the annual fee |